samedan logo

 
 
spacer
home > pmps > summer 2017 > factory of the future
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Factory of the Future

Despite strict administrative regulations, the pharmaceutical sector is an increasingly competitive marketplace where established industry giants are vying against providers of cheaper, generic alternatives. Meanwhile, new companies – formed through merger and acquisition activities – are approaching the field.

Existing players are under increasing pressure. Delivering the highest quality products and accurate information on packaging is now more critical than ever before. Medications need to not only appeal to the consumer with clear guidelines on safe use, ingredients and side effects, but must also be compliant with the rigorous stateimposed standards.

Every package must contain accurate data and clear labelling before it can be distributed to healthcare and pharma organisations en masse. Given the unique regulations surrounding the sale of therapeutics and similar medical products compared to other goods, drug developers are required to take special care on their production lines, while keeping operational costs low.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.


spacer
Eva Weber, Senior Product Marketing Manager for SDKs, is responsible for product marketing activities for ABBYY Europe’s technology licensing products. With her extensive expertise, Eva is a key driver of the company's activities around the usage of OCR within the machine vision industry, including educational webinars and press articles. 
spacer
Eva Weber
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Theravectys Announces $20M Funding Round

THERAVECTYS, the world leading pioneer in lentiviral vector technology, announced today a fully subscribed $20M funding round. This funding will be used to progress the Theravectys pipeline by driving several vaccine candidates, including their COVID vaccine, into phase 1 and 1-2 clinical trials.
More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement